Incidences of adverse events ( AEs ) , serious AEs ( SAEs ) , discontinuations due to AEs , deaths , AEs of special interest related to interleukin-1 inhibition and T2DM disease , and laboratory abnormalities related to haematology and biochemistry parameters were reported .